BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30910997)

  • 1. Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.
    Xu X; Liu Q; Zhang C; Ren S; Xu L; Zhao Z; Dou H; Li P; Zhang X; Gong Y; Shao C
    Cell Death Dis; 2019 Mar; 10(4):282. PubMed ID: 30910997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
    Villalonga-Planells R; Coll-Mulet L; Martínez-Soler F; Castaño E; Acebes JJ; Giménez-Bonafé P; Gil J; Tortosa A
    PLoS One; 2011 Apr; 6(4):e18588. PubMed ID: 21483692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
    Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence.
    Luo H; Yount C; Lang H; Yang A; Riemer EC; Lyons K; Vanek KN; Silvestri GA; Schulte BA; Wang GY
    Lung Cancer; 2013 Aug; 81(2):167-73. PubMed ID: 23683497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype.
    Wiley CD; Schaum N; Alimirah F; Lopez-Dominguez JA; Orjalo AV; Scott G; Desprez PY; Benz C; Davalos AR; Campisi J
    Sci Rep; 2018 Feb; 8(1):2410. PubMed ID: 29402901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.
    Kumamoto K; Spillare EA; Fujita K; Horikawa I; Yamashita T; Appella E; Nagashima M; Takenoshita S; Yokota J; Harris CC
    Cancer Res; 2008 May; 68(9):3193-203. PubMed ID: 18451145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development.
    Song H; Sun B; Liao Y; Xu D; Guo W; Wang T; Jing B; Hu M; Li K; Yao F; Deng J
    Int J Cancer; 2019 Feb; 144(4):777-787. PubMed ID: 29992578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
    Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
    Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3.
    Huang B; Vassilev LT
    Aging (Albany NY); 2009 Sep; 1(10):845-54. PubMed ID: 20157557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
    Pozo N; Zahonero C; Fernández P; Liñares JM; Ayuso A; Hagiwara M; Pérez A; Ricoy JR; Hernández-Laín A; Sepúlveda JM; Sánchez-Gómez P
    J Clin Invest; 2013 Jun; 123(6):2475-87. PubMed ID: 23635774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway.
    Zhang F; Li M; Wu X; Hu Y; Cao Y; Wang X; Xiang S; Li H; Jiang L; Tan Z; Lu W; Weng H; Shu Y; Gong W; Wang X; Zhang Y; Shi W; Dong P; Gu J; Liu Y
    Drug Des Devel Ther; 2015; 9():3969-87. PubMed ID: 26309394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Awakening p53 in senescent cells using nutlin-3.
    Schug TT
    Aging (Albany NY); 2009 Oct; 1(10):842-4. PubMed ID: 20157556
    [No Abstract]   [Full Text] [Related]  

  • 18. Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.
    Polański R; Noon AP; Blaydes J; Phillips A; Rubbi CP; Parsons K; Vlatković N; Boyd MT
    Cancer Lett; 2014 Oct; 353(2):211-9. PubMed ID: 25067787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
    Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
    Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension.
    Mouraret N; Marcos E; Abid S; Gary-Bobo G; Saker M; Houssaini A; Dubois-Rande JL; Boyer L; Boczkowski J; Derumeaux G; Amsellem V; Adnot S
    Circulation; 2013 Apr; 127(16):1664-76. PubMed ID: 23513067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.